Sponsor:
United Therapeutics
Code:
NCT07224763
Conditions
ESRD (End-Stage Renal Disease)
Kidney Transplantation
Xenotransplantation
Eligibility Criteria
Sex: All
Age: 40 - 70
Healthy Volunteers: Not accepted
Interventions
GGTA1 KO Thymokidney
Brief summary:
Conditions
ESRD (End-Stage Renal Disease)
Kidney Transplantation
Xenotransplantation
Study ID
NCT07224763
Start date
Nov, 2026
Status verified date
Sep, 2026
Completion date
Nov, 2076
Anticipated
Primary completion date
Nov, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 40 - 70
Healthy Volunteers: Not accepted
Enrollment
50 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: GGTA1 KO Thymokidney
Interventions
GGTA1 KO Thymokidney
Primary outcome measure
Central contacts
Locations
New York University Langone Health
Recruiting
New York, New York, United States, 10016
Contacts
Principal Investigator:
Robert A Montgomery, MD, DPhil
Sponsor
United Therapeutics
Last update posted
Sep 9, 2026
Last verified
Sep, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by United Therapeutics on 2026-09-09.